RecruitingPhase 4NCT05642806

Comparison of Immune Profiles in Chronic Rhinosinusitis Patients After Mepolizumab Treatment

Sponsor

St. Paul's Sinus Centre

Enrollment

90 participants

Start Date

Jul 1, 2023

Study Type

INTERVENTIONAL

Conditions

Asthma Chronic Rhinosinusitis With Nasal Polyps Chronic Rhinosinusitis Without Nasal Polyps

Summary

This study aims to analyze the immune profiles of patients with Chronic Rhinosinusitis with Nasal polyps (CRSwNP) with and without asthma before and after Mepolizumab. A group of participants with CRS without nasal polyps (CRSsNP) with asthma will be included to compare their immune profiles to CRSwNP.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is examining how a biologic drug called mepolizumab (which targets a protein involved in airway inflammation) changes the immune system in people with chronic sinusitis with nasal polyps. It is comparing these immune changes to people with chronic sinusitis without polyps who do not receive the drug. **You may be eligible if...** - You are over 19 years old - You have chronic sinusitis with nasal polyps (with or without asthma), OR chronic sinusitis without polyps but with asthma - Women of childbearing age must agree to use contraception and have a negative pregnancy test **You may NOT be eligible if...** - You do not have chronic sinusitis or the specified asthma profile - You are pregnant or unable to use contraception - You have another serious medical condition that would interfere with participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALMepolizumab

Mepolizumab will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

OTHERPlacebo

Placebo will be administered subcutaneously (SC) every 4 weeks for a total of 24 weeks

Locations(1)

St. Pual's Sinus Centre

Vancouver, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05642806

Related Trials

ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia

NCT073996659 locations

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

NCT06307665135 locations

Personalized Environment and Genes Study

NCT003412371 location

PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

NCT069811693 locations

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589143 locations